Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Monthly Darbepoetin Alfa Dosing for Correction of Anemia in Non-dialysis Chronic Kidney Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age~* Diagnosis of chronic kidney disease with eGFR of 15-59 mL/min/1.73 m2 (MDRD equation)~* Two consecutive screening Hb values taken at least 7 days apart must each be \<10.0 g/dL~* TSAT ≥ 15%~Exclusion Criteria:~* Upper or lower GI bleeding within 6 months before enrolment~* ESA use within 12 weeks before enrolment~* Uncontrolled hypertension~* Systemic haematologic disorders~* Prior history within 12 weeks before enrollment of events including: Acute myocardial ischemia, unstable angina, myocardial infarction, hospitalization for congestive heart failure, stroke or transient ischaemic attack, limb ischaemia, deep vein thrombosis, thromboembolism.~* Grand mal seizure within 6 months prior to enrolment~* Evidence of, or received chemotherapy or radiation therapy for, a malignancy within 5 years prior to enrolment.~* Red blood cell transfusion within 12 weeks prior to enrolment~* Androgen therapy within 8 weeks prior to enrolment~* Pregnancy or breast feeding, or inadequate contraception~* Currently receiving immunosuppressive therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Q2W (Type: ACTIVE_COMPARATOR): Q2W administration of darbepoetin alfa.
- QM (Type: ACTIVE_COMPARATOR): QM administration of darbepoetin alfa

Based on this trial design, predict the completion outcome and termination type (if applicable).